Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trofinetide (Primary)
- Indications Concussion
- Focus Therapeutic Use
- Sponsors Neuren Pharmaceuticals
- 27 Mar 2017 Status changed from suspended to discontinued.
- 09 May 2016 Status changed from recruiting to suspended as data from another study requires re-evaluation of study design.
- 09 Oct 2015 Planned End Date changed from 1 Oct 2015 to 1 Jun 2016, according to ClinicalTrials.gov record.